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We read with interest the data submitted by Batalla et al.
concerning plasma Lp(a) concentrations in 132 men aged
less than 50-years old admitted to hospital with acute
coronary syndromes. They report a multiple group compar-
ison (Kruskal Wallis test) indicating a significant difference
(p 5 0.003) between Lp(a) concentrations in four subgroups
divided according to the number of vessels with greater than
50% angiographic stenoses (i.e., 0, 1, 2 and 3 vessel disease).
Their data suggest that the patients with higher vessel scores
had higher plasma Lp(a) concentrations. Our previous
report (1) described plasma Lp(a) concentrations in 129
patients (mean age 60 6 11 years; 43 women) with chronic
stable angina who we assessed using a validated angio-
graphic scoring method (2) to take account of both mild and
severe angiographic stenoses. Analysis of our data indicated
that Lp(a) concentrations were significantly higher in pa-
tients with significant angiographic disease compared with
those without such disease. Having demonstrated a signif-
icant difference in Lp(a) concentration between those with
a vessel score of 0 and those with a vessel score greater than
0, it is not surprising that a multiple group analysis of Lp(a)
concentrations between subgroups of our patients divided
according to vessel score (as performed by Batalla et al.) also
indicated a statistically significant difference. However, we
wished to investigate the relationship between Lp(a) con-
centration and vessel score within the patients with angio-
graphic disease and, therefore, we excluded those with a
vessel score of zero from this analysis. Our data indicated
that the difference in Lp(a) concentration between patients
with 1, 2 and 3 vessel disease was not significant (p 5 0.3).
The distribution of the data in Batalla et al.’s study is
presented as the 5th to 95th percentiles rather than the more
conventional interquartile range (25th to 75th percentiles)
and consequently, it is difficult to compare the extent of
overlap between the subgroups in the two studies. Never-
theless, it would be interesting to know whether a similar
three-way analysis of their data would provide a statistically
significant result.
Subgroup analysis of our data according to gender indi-
cated that the difference in Lp(a) concentration between
those with and those without angiographic disease only
achieved statistical significance in women. Our failure to
demonstrate a significant difference in men is consistent
with the findings of other investigators (3) and is intriguing
in light of the fact that androgenic steroids are known to
significantly reduce Lp(a) concentrations (4). The discrep-
ancy with the findings of Batalla et al. may be related to the
difference in clinical presentation and, in particular, it is
important to consider the possibility that Lp(a) may act as
an acute phase reactant in patients with acute coronary
syndromes (5). Therefore, we believe that the data provided
by Batalla et al. are complementary to our own findings.
Their data also confirm and extend the results of other
authors (6) who have previously shown that plasma Lp(a)
concentrations are significantly raised in patients with un-
stable angina and correlate with plasma Troponin-T levels.
These findings suggest that Lp(a) may have an important
role in the pathophysiology of plaque instability in acute
coronary syndromes.
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Peak VO2 et al. For
Prognosis In Heart Failure?
Osada et al. (1) recently reported interesting data on the
3-year prognosis of 154 patients with a peak VO2 #14
ml/kg/min. It was found that amongst the variables studied
peak exercise systolic blood pressure and % predicted peak
VO2 were the two most important prognostic markers. We
would like to ask the authors whether they have included in
their statistical analyses the VE/VCO2-slope and the pres-
ence of very low body weight or weight loss, i.e., cardiac
cachexia?
In the methodology section, the authors stated that the
VE/VCO2-slope has been assessed. Nowhere in the paper
did the authors subsequently report these data, which is
unfortunate, particularly because a report published previ-
ously in the Journal of the American College of Cardiology
reported the very strong prognostic predictive power of the
VE/VCO2-slope, which was significantly independent of
peak VO2 (2). This finding has recently been confirmed by
others (3,4). Part of the quality of VE/VCO2-slope data
arises from its excellent reproducibility. The SD for re-
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